Pennsylvania Attorney General Josh Shapiro issued the following news release:. Attorney General Josh Shapiro today announced criminal charges against 51 people for selling heroin, fentanyl, illegal prescription opioids, cocaine, and other drugs in Allegheny County. Many of the arrests in today's roundup were for people considered mid-level drug dea
The American Herbal Products Association issued the following news release:. In a letter to the editor submitted to JAMA Open Network, American Herbal Products Association President Michael McGuffin stressed that the herbal products industry shares concerns about unapproved drugs masquerading as dietary supplements, as outlined in a recent article,
The pharmaceutical companies contribute large amounts of money to members of Congress and state legislatures to lobby them. Prescription drugs are so exorbitant that alternatives should be a right of the people. Amendment 3 would develop three research facilities to find cures for cancer and chronic diseases and provide $66 million of construction
The National Multiple Sclerosis Society issued the following news:. A generic equivalent of Ampyra, a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available.
-Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimers disease, Rett syndrome and other central nervous system diseases, today announced that the Company has received confirmation from the U.S. Food...
Oct. 19 Maryland Attorney General Brian Frosh on Friday appealed to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislatio
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2 a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma treated with BL-8040 in combination with KEYTRUDA..
Valley Cottage, NY 10/19/2018 A new study by FMI titled' Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027', has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run
Alzheon is a U.S. clinical-stage biopharmaceutical company developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Alzheon has offered to sell 2.5 million shares of its common stock in the offering, and the underwriters have an option for 30 days to purchase up to 375 thousand additiona
Macter International Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on October 27, 2018 at Karachi. Macter International Limited is amongst the leading Pharmaceutical companies in Pakistan. Macter is a public limited company and has a successful 30 years track record in the manufacturing of phar
Cantargia AB today presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 in a poster presentation at the ESMO Congress 2018 in Munich, Germany. The poster presentation with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein, in patients
Castle Creek plans to use this additional funding to support the late-stage development of an investigational drug, diacerein ointment. We are focused on developing CCP-020 as an important treatment for EBS and look forward to targeting the new investment from Fidelity and Valor towards the late-stage development of this investigational drug, said.
-Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford, CSCP, as Vice President, Supply Chain. Crawfords earlier experience includes supply chain, manufacturing and trade relations management
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING agonist, as monotherapy and in combination with KEYTRUDA , Merck s anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas. MK-1454 is one
Harrisburg, NC 10/19/2018 Global Generic Drugs Market Insights, Forecast To 2025; presents an in-depth assessment of the Generic Drugs including new developments, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, player profiles
Innate Pharma SA, today announced updated data from the Phase II trial evaluating the safety and efficacy of the combination of monalizumab and cetuximab in previously treated patients with recurrent and/or metastatic squamous cell carcinoma of the head& neck. The data will be discussed today at the ESMO 2018 Congress in Munich, Germany, by Profess
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA (R) treatment achie
Maryland Attorney General Brian Frosh appealed Friday to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislation violates th
Shares of Merrimack Pharmaceuticals Inc plunged in Fridays pre-market session after the clinical-stage oncology company announced it terminated a Phase 2 trial for its treatment of non-small cell lung cancer due to its failure to improve patients chances for survival. In the wake of the move, the Cambridge, Massachusetts- based company is starting
The University of California issued the following news release:. "Any tissue with compromised blood flow, whether due to trauma, stroke, or heart disease, could potentially be targeted by a treatment like this," said Emin Maltepe, MD, PhD, associate professor of pediatrics at UCSF and co-senior author of the paper. The new drug, called OMX-CV, was
Novotech, the largest Asia-Pacific- based CRO, has acquired Australasian specialist CRO Clinical Network Services, as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Early phase CNS clients, wishing to advance into later phase regio
The Medical Arts Health Research Group will carry out a phase 3 study in the research process, which if successful would lead next to Health Canada and U.S. Food and Drug Administration approval, with further followup research efforts carried out for the medication after public certification on a wider basis. As doctors, nurses and caregivers, find
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1 b trial investigating navicixizumab, OncoMed s anti-DLL4/VEGF bispecific antibody, in combination with paclitaxel in patients with...
-Paragon Biosciences today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma, a Paragon portfolio company. Paragon organized the $71.8 million investment in Castle Creek from respected firms, Fidelity Management& Research Company and Valor Equity Partners, for late-stage development of treatments for rare
The Parenteral Drug Association issued the following news release:. The Parenteral Drug Association is pleased to announce the formation of a PDA technical report team and a task force to advance projects to assist pharmaceutical manufacturers in key areas. Both projects are part of the overarching PDA/MSOP Manufacturing Intelligence Task Force,...